Home Blog Page 425

Homegrown Gaming Platform “Game On, Dreamers!” to Launch Singapore’s Largest Gaming PlayFest in August 2026

Strategic partnerships with CAPCOM and Social Seed announced as the Singapore-born platform aims to unite gamers, creators, esports and immersive experiences under one roof

SINGAPORE, March 26, 2026 /PRNewswire/ — “Game On, Dreamers!” will launch Singapore’s largest gaming playfest, Game On, Dreamers! Multiplayer Offline Digital Event (G.O.D. Mode) at Sands Expo & Convention Centre, Halls D, E & F from 7 to 9 August 2026.

The Singapore-born gaming lifestyle platform aims to bring together esports, game creators, cosplay communities and immersive gaming experiences in the large-scale festival designed “for gamers, by gamers”.

A preview event was held on 3 March in Singapore to introduce G.O.D. Mode — celebrating gaming culture and community while spotlighting Singapore’s growing role in the regional gaming, entertainment, and esports landscape.

A Festival Designed for Gamers

During the preview event, Game On, Dreamers! also formalised strategic collaborations through a Memorandum of Understanding (MOU) signing with global gaming company CAPCOM and leading user-generated content (UGC) creator network Social Seed. The partnerships will explore opportunities across content creation, community engagement and competitive gaming initiatives.

In his welcome address, Terence Kuek, Executive Producer of Game On, Dreamers!, shared that the August festival  is conceived as more than just a gaming conference or convention.

“With Game On, Dreamers!, we set out to create a gaming event for gamers and the community that surrounds them. At its heart, gaming is about connection, shared experiences and community — and that is what we want this playfest to celebrate”.

Inspired by the rallying cry “Play As One”, G.O.D. Mode is designed to unite gamers of all skill levels — from hardcore competitors to casual players and families — through a multi-layered festival experience.

The inaugural event is expected to occupy Halls D, E, and F at Sands Expo and Convention Centre, transforming the venue into an interactive gaming playground featuring themed zones including Dream World, Dream Battle, and Dream Play. The experience will evolve throughout the day and night, delivering a dynamic gaming atmosphere that spans immersive gameplay and competitive esports action.

Supported by the Singapore Tourism Board (STB), G.O.D Mode reflects ongoing efforts to strengthen Singapore’s appeal as a leading destination for diverse leisure experiences.

Game On, Dreamers! Multiplayer Offline Digital Event (G.O.D. Mode) is a homegrown event with global potential that adds a fresh dimension to our vibrant events calendar, reinforcing Singapore’s destination appeal. We are pleased to support this three-day festival, which will showcase Singapore as a dynamic hub for esports, while providing engaging experiences for both local enthusiasts and international visitors.” – Lilian Chee, Director, Sports, STB.

Powering the Creator Economy

At the preview event, Brian Tiong, Co-Founder of Liminal Entertainment and Director of Social Seed, highlighted the growing influence of user-generated content within the global gaming ecosystem.

Social Seed, the world’s largest UGC gaming creator network, connects developers, creators and brands through a collaborative marketplace. The platform currently hosts more than 10,000 community members, including over 9,000 game developers and 500 content creators, alongside thousands of games built within the ecosystem.

Brian shared insights into the explosive growth of platforms such as Roblox, which now boasts over 144 million daily active users globally and a thriving creator economy where top developers can earn significant revenue through their games.

Through its collaboration with Game On, Dreamers!, Social Seed will bring some of the world’s most prominent game creators and content personalities to Singapore, giving fans the opportunity to meet and engage with the talent behind globally popular games.

Separately, CAPCOM and G.O.D. will explore potential collaboration including publisher showcase participation, competitive and tournament programming featuring eligible CAPCOM titles, community and cosplay initiatives aligned with CAPCOM franchises, and joint promotional activities.

“Singapore continues to be an important market for gaming culture in Southeast Asia. We are excited to explore how our franchises can engage fans through competitive play, community showcases and curated experiences at G.O.D. Mode.” Mr Ricky Bian Li, Managing Director, CAPCOM Singapore Pte Ltd.

Elevating Esports and Gaming Infrastructure

Industry leaders also shared insights on the evolution of esports and the growing demand for infrastructure that supports competitive gaming experiences.

Shaun Tan, Founder and CEO of Dreamcore, emphasised the importance of building a holistic gaming ecosystem that goes beyond hardware and tournaments.

“Gaming today is no longer just about playing at home. It’s about building communities and experiences. Through Game On, Dreamers!, we hope to create a platform where gamers, creators and esports professionals can come together and share that passion.”

Meanwhile, Li Jianming, Founder and CEO of Zenway Productions, highlighted the role of professional broadcast infrastructure in expanding esports reach globally.

“While a physical venue can host thousands of fans, broadcast platforms allow esports events to reach millions worldwide. Our goal is to ensure Game On, Dreamers! delivers a premium esports experience that can be enjoyed both on-site and by audiences around the world.”

The esports programming at Game On, Dreamers! will feature both professional competitions and accessible community tournaments, with potential titles including popular esports games such as Street Fighter, Mobile Legends, Valorant, League of Legends and Dota 2. The event will also introduce family-friendly gaming activities and show matches to broaden participation.

A Singapore-Born Gaming Platform for the World

The organisers shared that the vision behind Game On, Dreamers! is to create a globally recognised gaming event originating from Singapore. The festival is timed to coincide with Singapore’s National Day celebrations in 2026, positioning it as a major cultural and entertainment highlight.

Supported by industry partners and gaming communities across the region, Game On, Dreamers! aims to establish Singapore as a key destination for gaming culture, esports and creator-driven entertainment.

“This is a gaming experience created by Singaporeans, in Singapore, for the world. We invite gamers, partners and the community to join us as we build something truly exciting together.” Terence Kuek, Executive Producer of Game On, Dreamers!

Further details on the official launch, event programming and participating partners will be announced in the coming months.

About Game On, Dreamers!

Game On, Dreamers! (G.O.D.) is a Singapore-based gaming culture platform focused on building large-scale live experiences that integrate esports, creators, communities and brands. It is operated by GameOn Dreamers (SG) Pte Ltd jointly powered by amc asia! (sg) Pte Ltd and Liminal Entertainment Pte Ltd.

SHEIN’s 2025 Global Circularity Study Highlights How Consumers Buy, Use and Manage Clothing

SINGAPORE, March 26, 2026 /PRNewswire/ — SHEIN, a global online fashion and lifestyle retailer, today released findings from its 2025 Global Circularity Study, offering insights into how SHEIN consumers purchase, use and manage clothing across its lifecycle.

Conducted between November and December 2025, the study surveyed 15,461 SHEIN customers aged 18 to 44 across 21 markets across the Americas, Asia-Pacific, Europe, Middle East and Africa. The study examines consumer behaviour across the clothing lifecycle, from purchase decisions, garment use and care, to end-of-life management, offering data-backed insights into how everyday consumers across the globe engage with fashion and circularity.

The study indicates that many behaviours commonly associated with circular fashion – such as repeated wear, repairing garments, and passing clothing on to others – already occur as part of everyday clothing practices.

At the same time, the results highlight that consumer decisions about clothing tend to be shaped by practical considerations, including price, fit and everyday usability. Together, these findings underscore the importance of designing systems and initiatives that promote circularity that work within the realities of consumers’ everyday clothing use.

Practical Considerations Shape Clothing Purchasing Decisions

Across markets surveyed, respondents reported that clothing purchases are primarily driven by practical considerations such as affordability, fit and lifestyle relevance.

When purchasing clothing online, finding the best price was the most frequently cited factor, with 71.6% of respondents reporting they always consider price. This was followed by availability of sizes that fit (66.7%), reflection of personal style (58.1%) and how well an item fits everyday lifestyle or changing needs (53.8%).

Many respondents (71.1%) also reported that they purchased fewer than 30 clothing items, whether from online sites or physical stores, in the past year. Taken as a whole, the responses show that consumers often balance cost, fit and everyday usefulness when making clothing purchases.

Clothing is Worn Repeatedly

Beyond purchasing behaviour, the study looked at how consumers wear and maintain clothing after purchase. Respondents reported high levels of repeat wear across core clothing categories such as everyday basics, outerwear, footwear and activewear.

Between 36.2% and 41.1% of respondents reported wearing their SHEIN clothing in these categories more than 50 times, while 16.4% to 19.9% said they wear them between 31 and 50 times.

When deciding how long to keep clothing, consumers prioritised factors including comfort (88.1%), fit (82.2%), visible wear and tear (64.4%), and ease of care (63.3%), suggesting that garments tend to remain in use as long as they continue to meet practical needs.

How Consumers Define Circular and Sustainable Clothing

The study also explored how consumers interpret the concepts of circularity and sustainability in fashion.

When asked about what characteristics best define circular or sustainable clothing, 47.0% of respondents selected durability and long-lasting quality, while 37.8% cited clothing made with lower-impact materials, such as recycled fibres or materials produced using less water. By contrast, fewer than 10% of respondents associated sustainable clothing with higher prices or fewer style options.

These findings suggest that consumers often interpret sustainability through practical product characteristics, particularly how long clothing lasts and how easily it can continue to be worn.

Reuse is Common, Recycling Faces Practical Barriers

When clothing is no longer needed, respondents most often keep garments in circulation through familiar reuse pathways. Across all markets surveyed, giving clothing to friends or family was the most common approach (82.6%), followed by donating to charities or non-profit organisations (69.0%).

Repair also plays a role in extending garment life, with 61.7% of respondents saying they had repaired or made alterations. Among those who had not repaired clothing in the past year, 58.3% said that having the skills or knowledge to repair would encourage them to do so.

Participation in formal recycling systems was lower, with 37.2% of respondents reporting that they recycled clothing in the past year. Among those who did not recycle clothing, the most frequently cited factors that would encourage recycling were knowing where or how to recycle (43.6%) and having convenient or nearby recycling facilities (40.3%).

These results suggest that access to more convenient systems and local infrastructure, and greater awareness of available options can influence consumers to participate in activities that keep clothing in circulation for longer and support a circular economy.

Designing Circularity for Real Life

Taken together, the data gathered from this study highlights how practical considerations shape how consumers engage with clothing throughout its lifecycle.

Respondents also expressed the strongest interest in initiatives that enable direct participation, such as resale through SHEIN Exchange (43.8%) and physical take-back bins for donation or recycling (43.1%). By comparison, informational initiatives such as digital product passports (15.6%) or garment information about environmental footprint (18.8%) attracted lower levels of interest.

The date indicates that initiatives that promote circularity may be more effective when they align with consumers’ everyday routines, and provide practical ways for people to repair, reuse or recycle clothing.

Insights from the 2025 Global Circularity Study help deepen SHEIN’s understanding of how consumers buy, use and manage clothing, supporting its efforts to develop impactful initiatives that are aligned with how consumers truly use their clothing in everyday life.

Read the full 2025 Global Circularity Study here.

 

 

CLOU Unveils Aqua-C3.0 Ultra High-Density Energy Storage System at Solar & Storage Live Africa

JOHANNESBURG, March 26, 2026 /PRNewswire/ — CLOU Electronics launched its next-generation energy storage solution: Aqua-C3.0 Ultra 10+ feet DC/AC All-In-One Liquid-Cooled Energy Storage System at Solar & Storage Live Africa.

Aqua-C3.0 Ultra 10+ feet DC/AC All-In-One Liquid-Cooled Energy Storage System
Aqua-C3.0 Ultra 10+ feet DC/AC All-In-One Liquid-Cooled Energy Storage System

Featuring 587 Ah cells, Aqua-C3.0 Ultra is available in two configurations—DC/AC All-In-One version and DC version. This product series features CLOU’s 3rd-generation pack design, reducing components by 30% compared to the previous generation. The DC version achieves an industry-leading energy density of 535 kWh/m². The DC/AC All-In-One version incorporates CLOU’s second-generation SiC string PCS, cutting inverter volume by 50%. With a system energy density of 480 kWh/m², both specifications represent industry-leading benchmarks.

Compared to 20-foot containerized systems of 5MWh, 6.251MWh, and 7MWh+, the product achieves the optimal balance of capacity, dimensions, and weight. Its design accommodates most global port lifting operations and overland transport requirements. This translates to a 11% to 46% reduction in per-Wh overall transportation costs.

Utilizing a fully liquid-cooled solution that covers the battery compartment, electrical compartment, and built-in PCS, the system ensures efficient operation across an extended temperature range of -30°C to 50°C (55℃ optional).

The product has also established a multi-layer protection system covering “early thermal runaway warning, fire suppression, and explosion prevention”, meeting stringent international fire safety design standards, including UL 9540A and NFPA 69.

In structural and protective safety, the solution complies with the rigorous seismic design requirements of IEEE 693. It achieves the highest corrosion resistance rating of C5-M and an IP55 protection rating.

The product is equipped with CLOU’s Version 7.0 BMS, featuring high-precision data acquisition and 0.5A active balancing capabilities. This enables AI-powered cell health pre-diagnosis and early fault warnings.

The DC/AC All-In-One version incorporates grid-forming SiC PCS technology, cutting on-site installation and commissioning time by 50%. It supports essential grid-forming functions including primary frequency regulation, inertia response, black start, and wide-band oscillation suppression.

CLOU has successfully delivered projects across Rwanda, Cape Verde, Zimbabwe, and beyond. The Rwanda project, commissioned as early as 2018, marked an early milestone in the company’s strategic expansion across the continent. As Africa accelerates its energy transition, demand grows for secure, flexible, and efficient energy storage solutions. CLOU’s launch of new storage products at a premier African energy exhibition directly addresses this need while reinforcing its market commitment.

Sungrow Powers Solar & Storage Live Johannesburg with Next-Generation C&I and Utility Solutions

JOHANNESBURG, March 26, 2026 /PRNewswire/ — Sungrow, the global leading PV inverter and energy storage system (ESS) provider, participated in Solar & Storage Live Johannesburg 2026 with a focused showcase of integrated solar and storage solutions designed to support the evolving needs of the region’s commercial, industrial, and utility-scale energy markets.

Sungrow Johannesburg Solar&Storage
Sungrow Johannesburg Solar&Storage

Across Africa, businesses are increasingly looking for smarter ways to manage energy usage, improve reliability, and optimise operational costs. To better address the diverse energy challenges across the continent, Sungrow continues to develop and deploy solutions specifically adapted to local operating environments. From managing grid variability to supporting flexible deployment across different industries, Sungrow’s technologies are engineered for reliability and scalability. By combining robust hardware with intelligent energy management capabilities, Sungrow enables organisations across the region to build more efficient and adaptable energy systems aligned with their operational needs.

At this year’s event, Sungrow highlighted a comprehensive portfolio of solutions tailored to local market conditions. These include advanced C&I storage systems, utility-scale energy storage platforms, high-efficiency inverters, and scalable microgrid architectures that support both grid-connected and off-grid applications.

Among the solutions on display, a highlight is the Sungrow PowerKeeper, a DC-coupled energy storage system designed specifically for commercial and industrial environments. What sets PowerKeeper apart is its modular, stackable design, allowing capacity to be expanded easily as energy needs grow. This flexible architecture enables businesses to scale their storage system over time without the need for major system redesigns. PowerKeeper forms part of Sungrow’s broader strategy to deliver more adaptable and intelligent energy management solutions for businesses across the region.

Sungrow’s integrated Microgrid Solution demonstrates how hybrid energy systems can combine solar, energy storage, and conventional generation to provide stable and intelligent energy management in complex operating environments. This is particularly valuable in the mining sector, where remote operations and energy-intensive processes require resilient and flexible power solutions. By integrating renewable generation with advanced storage and control systems, microgrids can support remote mining sites and other industrial facilities that depend on reliable, well-managed energy infrastructure.

In addition to PowerKeeper and Microgrid, Sungrow presented its SG465 inverter, designed to deliver high performance and reliability for large commercial and utility-scale projects. Visitors will also gain insight into the latest evolution of Sungrow’s utility-scale energy storage platform, PowerTitan 3.0, developed to enhance safety, scalability, and lifecycle performance for large energy infrastructure projects.

“Sungrow has been operating in South Africa for nine years and has built a strong regional presence to support projects across the continent,” said Nigel Sun, President of Sungrow Sub-Saharan Africa. Sungrow sales and solution teams are based across West, East, Central, and Southern Africa. Today, we have a growing network of more than five channel partners, and together with our partners, we have already delivered key projects in South Africa and across markets such as Botswana, the DRC, and Zambia, to name a few. Our focus is to work closely with EPCs, installers, and asset owners to deploy integrated solar and storage solutions that strengthen energy resilience while improving long-term project returns.”

Throughout the exhibition, Sungrow’s technical and regional teams will engage with industry stakeholders on deployment strategies, system optimization, and long-term service support. By showcasing a diversified technology portfolio, Sungrow reinforces its role as a long-term partner in Southern Africa’s transition to resilient and sustainable energy systems.

Through continuous innovation, regional investment, and strong partnerships, Sungrow remains committed to advancing reliable, future-ready energy infrastructure across Africa.

About Sungrow
Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 29 years. As of Dec 2025, Sungrow has installed over 1000 GW of power electronic converters worldwide. The company is recognized as the world’s most bankable PV inverter and energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experiences. At Sungrow, we’re committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com/en

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

SUZHOU, China, March 26, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress.

Key Highlights

  • KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-line HER2-positive GC, with data presented as a LBA oral presentation at the 2025 ESMO Congress. The first NDA was accepted by the NMPA and received priority review status, followed by successful completion of drug registration inspection and GMP compliance inspection, and is on the verge of market launch. Patient enrollment has been completed for two phase III studies in first-line HER2-positive BC and neoadjuvant treatment, while the phase III study in adjuvant treatment for BC has been initiated.
  • JSKN003 (Anbenitamab repodatecan), leveraging its “high efficacy, low toxicity” advantages, received two BTDs from the CDE and three international designations from the FDA (BTD, ODD, FTD) in 2025. Promising efficacy and safety data from multiple studies were presented at the ASCO Annual Meeting and ESMO Congress. Four phase III clinical studies are currently ongoing including second-line HER2-positive BC, HER2‑low BC, PROC, and HER2‑positive CRC, with patient enrollment completed for the phase III study in second-line HER2-positive BC.
  • JSKN016 has enrolled over 460 patients in total across phase I and II studies, with dose expansion and dose selection completed. After confirming efficacy in later-line lung cancer and breast cancer, first-line combination chemotherapy/immunotherapy have been explored, and a phase III study in TNBC has been initiated. Additionally, high-concentration subcutaneous formulation of JSKN016 has been approved for clinical development in Australia.
  • JSKN033 completed POC data accumulation and dose optimization confirmation in second-line CC. The POC cohort in second-line EC is currently enrolling. JSKN033 is also advancing phase II exploration in lung cancer and initiating a phase II clinical study in combination with chemotherapy for first-line CC. Through its ADC/IO combination strategy, JSKN033 continues to strengthen pan-tumor and all comers.
  • Leveraging modular and iterative technology platforms, innovative molecules continue to be generated and efficiently advanced into clinical development. JSKN022 has now progressed to the sixth dose‑escalation cohort, showing preliminary efficacy and favorable safety. JSKN027 received approval for phase I clinical study, and the first patient was dosed. JSKN021 presented preclinical data at the AACR Annual Meeting, and its IND application has been accepted by the CDE.

Financial Summary

  • For the year ended December 31, 2025, we recorded total revenue of RMB 566.24 million. Meanwhile, product revenue (attributed to the Company) amounted to RMB 130.13 million.
  • For the year ended December 31, 2025, our R&D expenditure amounted to RMB 572.16 million, representing a year-on-year increase of 41.57%.
  • For the year ended December 31, 2025, we recorded loss for the year of RMB 113.95 million.
  • We have a healthy financial position, with cash reserves of RMB 1,350.32 million as of December 31, 2025.

Business Highlights

Product Pipeline

Leveraging its proprietary core technology platforms, including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload conjugation, and high-concentration subcutaneous formulation, the Company has built a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge fields such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies. Notably, Envafolimab (KN035), the world’s first subcutaneous PD-(L)1 inhibitor, has been approved for marketing. The National Medical Products Administration (NMPA) has accepted the new drug application (NDA) for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer (GC). In addition, two bispecific ADC candidates are currently in phase III clinical trials, while several other bispecific ADCs and dual-payload ADCs are advancing rapidly in clinical development.

KN035 (Envafolimab)

KN035, an innovative anti-tumor immunotherapy drug, is the first subcutaneously injectable PD-(L)1 inhibitor worldwide and single-domain antibody in oncology. Envafolimab offers significant advantages in convenience and compliance by avoiding intravenous infusion and can be administered in just 30 seconds, making it particularly suitable for frail, elderly, or IV-intolerant patients. Envafolimab has been granted three Orphan Drug Designations (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced biliary tract cancer, soft tissue sarcoma and gastric cancer and gastroesophageal junction cancer (GC/GEJ); it has been granted Breakthrough Therapy Designation (BTD) by the NMPA for the treatment of unresectable or metastatic solid tumors with high tumor mutation burden (TMB-H).

Events during the Reporting Period

  • In June 2025, data from three phase II studies of Envafolimab (either as monotherapy or combination therapy) were presented as posters at the American Society of Clinical Oncology (ASCO) Annual Meeting, with data from additional eight studies published online.
  • In August 2025, a real-world study results of Envafolimab in advanced lung cancer were published in Thoracic Cancer.
  • In October 2025, data from six phase II clinical studies of Envafolimab in combination regimens were presented as posters at the 2025 European Society for Medical Oncology (ESMO) Congress, demonstrating robust efficacy across multiple solid tumor types, including biliary tract cancer, cervical cancer (CC), and lung cancer.
  • In December 2025, the phase II clinical study results of Envafolimab in combination with chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) were published in BMC Medicine.
  • In December 2025, Envafolimab was granted ODD by the FDA for the treatment of GC/GEJ.

Events after the Reporting Period

  • In January 2026, the NDA for Envafolimab in combination with the Gemcitabine and Oxaliplatin (GEMOX) regimen as first-line treatment for unresectable or metastatic biliary tract cancer was accepted by NMPA.

KN026 (Anbenitamab)

KN026 is a HER2 heterodimeric bispecific antibody (BsAb) that can simultaneously bind two non-overlapping epitopes of HER2, leading to HER2 signal blockade. Through antibody-induced receptor clustering, it enhances ADCC and CDC effects while promoting the down-regulation of HER2 receptors on the cell surface. KN026 has been granted ODD by the FDA for the treatment of HER2-positive or low expressing GC; it has been granted BTD by NMPA for the treatment of patients with HER2-positive GC/GEJ who have failed first-line standard treatment.

Events during the Reporting Period

  • In January 2025, the results of phase II clinical study of KN026 in combination with docetaxel as first-line treatment for HER2-positive recurrent or metastatic breast cancer (BC) were published in Cancer Communications.
  • In March 2025, the results of phase II clinical study of KN026 in combination with KN046 for the treatment of advanced HER2-positive solid tumors (excluding BC) were published in Signal Transduction and Targeted Therapy.
  • In April 2025, phase II/III clinical study of KN026 in combination with chemotherapy as second-line or above treatment of HER2-positive GC (including GEJ), completed the first interim analysis and met the pre-specified primary endpoint of progression-free survival (PFS) and overall survival (OS). KN026 is the first HER2 bispecific antibody to demonstrate positive results in the second-line treatment of GC.
  • In April 2025, enrollment of all patients was completed in the phase III clinical study of KN026 combined with albumin-bound docetaxel HB1801 as first-line treatment for HER2-positive recurrent or metastatic BC.
  • In June 2025, the results of phase II clinical study of KN026 in combination with KN046 for the treatment of HER2-positive BC were published in Clinical Cancer Research.
  • In August 2025, enrollment of all patients was completed in the phase III clinical study of KN026 in combination with albumin-bound docetaxel HB1801 as neoadjuvant treatment for early or locally advanced HER2-positive BC.
  • In September 2025, the NDA for KN026 in combination with chemotherapy for the treatment of patients with HER2-positive locally advanced, recurrent or metastatic GC/GEJ who have failed at least one prior systemic therapy was accepted by the NMPA and received priority review status.
  • In October 2025, the interim analysis results of the phase III clinical study of KN026 were presented as a late-breaking abstract (LBA) oral presentation at the 2025 ESMO Congress. KN026 demonstrated robust PFS and OS benefits in trastuzumab-pretreated patients with second- or third-line HER2-positive GC/GEJ, with the potential to change clinical guidelines for second-line and above GC treatment.
  • In November 2025, the phase II clinical study results of KN026 in HER2-positive GC/GEJ were published in Cancer Communications.
  • In December 2025, KN026 successfully passed the drug registration inspection (pharmaceutical) and Good Manufacturing Practice (GMP) compliance inspection.
  • The phase II clinical study of KN026 in combination with chemotherapy (with or without Enlonstobart) as first-line treatment for HER2-positive locally advanced or metastatic GC/GEJ has been initiated and is progressing smoothly.

Events after the Reporting Period

  • In January 2026, the phase III clinical study results of KN026 in patients with HER2-positive GC/GEJ were published in Annals of Oncology, a top-tier oncology journal.
  • In March 2026, the first patient was dosed in the phase III clinical study of KN026 in combination with albumin-bound docetaxel HB1801 and chemotherapy as adjuvant treatment for HER2-positive BC.

Expected Milestones in 2026 (from Q2 2026)

  • KN026 for second-line and above HER2‑positive GC/GEJ will receive marketing approval in China.
  • Phase III data release and NDA submission for KN026 in neoadjuvant HER2‑positive BC will be completed.
  • Phase III data release and NDA submission for KN026 in first‑line HER2‑positive BC will be completed.

JSKN003 (Anbenitamab repodatecan)

JSKN003 is developed by site-specific conjugation to the Fc glycans of KN026, resulting in a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4. JSKN003 binds to two HER2 epitopes on tumor cells and release topoisomerase I inhibitors upon internalization, exerting anti-tumor effects. Compared to most of ADCs, JSKN003 demonstrates better serum stability, reduced hematological toxicity, and stronger tumor inhibition and bystander effect, resulting in significantly wider therapeutic window. JSKN003 has been granted Fast Track Designation (FTD) (All comer) and BTD (HER2 expression) for platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (PROC) and who have received prior treatment with bevacizumab; It has also been granted two BTDs by the NMPA for PROC and HER2-positive advanced colorectal cancer (CRC) that has failed prior oxaliplatin, fluorouracil, and irinotecan therapy. In addition, JSKN003 has been granted ODD by the FDA for GC/GEJ.

Events during the Reporting Period

  • In February 2025, JSKN003 received approval from the CDE to initiate a phase III clinical study to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) as second-line or above treatment for HER2-positive advanced BC, and the first patient was dosed in the same month.
  • In February 2025, the first patient was successfully dosed in a phase III clinical study to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of PROC. The trial is now undergoing smoothly.
  • In March 2025, JSKN003 was granted BTD by the CDE for the treatment of PROC, not restricted to HER2 expression levels.
  • In June 2025, results of three pooled analysis from the phase I study in Australia and the phase I/II study in China evaluating the efficacy and safety of JSKN003 in non-primary platinum-refractory PROC, heavily pretreated HER2-positive BC and advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors were presented at the 2025 ASCO Annual Meeting. 
  • In June 2025, results of a preclinical study of JSKN003 were published in RSC Chemical Biology.
  • In July 2025, JSKN003 was granted ODD by the FDA for the treatment of GC/GEJ.
  • In July 2025, JSKN003 received FDA IND approval to initiate a phase II clinical study in the United States for the treatment of PROC, regardless of HER2 expression level.
  • In September 2025, enrollment of all patients was completed in the phase III clinical study of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced BC.
  • In October 2025, JSKN003 was granted BTD by the CDE for the treatment of HER2-positive advanced CRC that has failed prior treatment with oxaliplatin, fluorouracil, and irinotecan.
  • In October 2025, results from two clinical studies of JSKN003 (in primary platinum-refractory ovarian cancer and HER2-positive metastatic CRC) and the design of a phase III study of JSKN003 versus investigator’s choice of chemotherapy for PROC were presented at the 2025 ESMO Congress. The favorable efficacy and safety data demonstrated JSKN003’s differentiated advantages of “high efficacy, low toxicity” and its broad-spectrum potential across tumor types and HER2 expression levels, highlighting its promising clinical prospects.
  • In October 2025, JSKN003 was approved by the CDE to initiate a phase III clinical study to evaluate the efficacy and safety of JSKN003 versus investigator’s choice of regimen (regorafenib/fruquintinib/trifluridine tipiracil) in HER2-positive advanced CRC patients who have failed prior oxaliplatin, fluorouracil, and irinotecan therapy. The first patient was dosed in February 2026.
  • In October 2025, JSKN003 was granted FTD by the FDA for the treatment of PROC, regardless of HER2 expression level.
  • In December 2025, JSKN003 was granted BTD by the FDA for the treatment of advanced or metastatic HER2-expressing PROC in patients previously treated with bevacizumab.
  • The phase III clinical study of JSKN003 for the treatment of unresectable locally advanced or metastatic HER2-low expressing BC is undergoing smoothly.
  • The phase II clinical study of JSKN003 in combination with KN026, immunotherapy (IO), or chemotherapy as first-line and perioperative treatment for HER2-positive GC/GEJ has been initiated and is undergoing smoothly.

Expected Milestones in 2026 (from Q2 2026)

  • Data readout and pre-BLA submission will be completed for the phase III clinical study of JSKN003 as second-line or above treatment for HER2-positive BC.
  • Patient enrollment will be completed for phase III clinical study of JSKN003 in PROC.
  • Patient enrollment will be completed for phase III clinical study of JSKN003 as later-line treatment for HER2‑low BC.

JSKN016

JSKN016 is a TROP2/HER3 targeting bispecific ADC developed using the proprietary single-domain antibody and bispecific antibody platforms. It is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a DAR of 4. JSKN016 binds to TROP2 and/or HER3 on tumor cells and release topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects.

Events during the Reporting Period

  • The phase I and II clinical studies of JSKN016 have enrolled over 460 patients cumulatively, with dose expansion and dose selection completed.
  • Patient enrollment was completed in cohort expansion for JSKN016 monotherapy as later-line treatment for HR‑positive BC.
  • The phase II clinical study of JSKN016 in combination with capecitabine for the treatment of patients with HR‑positive BC, who have been pretreated with CDK4/6 but not received prior chemotherapy is undergoing smoothly.
  • In December 2025, the phase II clinical study of JSKN016 in combination with oral SERD for the treatment of CDK4/6‑pretreated HR‑positive, HER2‑negative BC was approved by the CDE, and the first patient was dosed in February 2026.
  • The phase II clinical study of JSKN016 monotherapy in later‑line treatment of driver gene‑positive (EGFR mutation/rare mutation) non‑small cell lung cancer (NSCLC) has completed efficacy confirmation.
  • The phase II clinical study of JSKN016 in combination with furmonertinib as first‑line and second‑line treatment for EGFR‑mutant NSCLC is progressing smoothly.
  • The phase II clinical study of JSKN016 in combination with ivonescimab and carboplatin as first‑line treatment for driver gene‑negative NSCLC is progressing smoothly.

Events after the Reporting Period

  • In March 2026, the first patient was dosed in the phase III clinical study of JSKN016 versus investigator’s choice of regimen for the treatment of unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC) in patients who have failed at least two prior lines of systemic therapy.
  • In March 2026, the phase I clinical study of the high-concentration subcutaneous formulation of JSKN016 for the treatment of advanced solid tumors was approved by the Bellberry Human Research Ethics Committee in Australia.

Expected Milestones in 2026 (from Q2 2026)

  • Pre‑IND communication for the combination study of JSKN016 in CDK4/6‑pretreated HR‑positive BC will be completed in the United States.
  • The phase I clinical study of the subcutaneous formulation of JSKN016 in Australia will complete the first patient dosing.
  • Results of JSKN016 monotherapy in TNBC and HR‑positive BC will be presented.
  • Results of JSKN016 monotherapy and combination therapy in NSCLC will be presented.
  • Phase III clinical study of JSKN016 in combination therapy as first‑line treatment for NSCLC will be initiated.

JSKN033

JSKN033 is an independently developed high-concentration subcutaneous formulation, combining the ADC (JSKN003) with PD-L1(Envafolimab). JSKN033 combines the benefits of immunotherapy and ADCs while enhancing safety and convenience through subcutaneous administration.

Events during the Reporting Period

  • The phase I and II clinical studies of JSKN033 have enrolled approximately 130 patients cumulatively.
  • In December 2025, the phase II clinical study application for JSKN033 in combination with platinum‑based chemotherapy (with or without bevacizumab) as first‑line treatment for advanced CC was accepted by the CDE, and was officially approved in March 2026.
  • Patient enrollment was completed in two dose cohorts of JSKN033 monotherapy as second‑line or above treatment for CC, with POC data accumulation and dose optimization confirmed.
  • Enrollment is ongoing for the POC cohort of JSKN033 monotherapy as second‑line or above treatment for endometrial cancer (EC).
  • The phase II clinical study of JSKN033 in HER2‑mutant or HER2‑expressing NSCLC is progressing smoothly.

Expected Milestones in 2026 (from Q2 2026)

  • The phase II clinical study of JSKN033 in combination regimens as first‑line treatment for CC will be initiated.
  • Registrational clinical study of JSKN033 as later‑line treatment for CC (all‑comer) will be initiated.

JSKN022

JSKN022 is a bispecific single-domain antibody targeting both PD-L1 and integrin αvβ6, developed through antibody-directed evolution. It is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a DAR of 4. Upon binding to PD-L1 and/or integrin αvβ6 on the surface of tumor cells, JSKN022 can release topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects. Additionally, JSKN022 blocks the binding of PD-L1 and PD-1, thereby activating antitumor immune responses. Simultaneously, by blocking integrin αvβ6, it inhibits the production of TGFB 1/3 and modulates the tumor immune microenvironment.

Events during the Reporting Period

  • In April 2025, preclinical data of JSKN022 were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting. Preclinical data demonstrate that JSKN022 exhibits potent antitumor activity in both in vitro and in vivo models against tumor cells expressing integrin αvβ6 and/or PD-L1.
  • In October 2025, JSKN022 was approved by the CDE to initiate a phase I clinical study for the treatment of advanced malignant solid tumors, and the first patient was dosed in the same month. The study has now progressed to the sixth dose‑escalation cohort, with preliminary efficacy and favorable safety observed.

Expected Milestones in 2026 (from Q2 2026)

  • Dose escalation and dose expansion for JSKN022 will be completed.

JSKN027

JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody’s Fc region – maintaining a strong safety profile while unlocking potent anti-tumor activity. JSKN027’s efficacy stems from a unique three-fold synergistic mechanism. Beyond the standard ADC effects of targeted cell killing and bystander activity, it also inhibits tumor angiogenesis by blocking VEGF/VEGFR2 signaling and reverses immune suppression by disrupting the PD-1/PD-L1 checkpoint. This integrated attack enhances overall anti-tumor power and is anticipated to help overcome therapeutic resistance.

Events after the Reporting Period

  • In March 2026, JSKN027 was approved by the CDE to initiate a phase I clinical study for the treatment of advanced malignant solid tumors, and the first patient was dosed in the same month.

Expected Milestones in 2026 (from Q2 2026)

  • Dose escalation and dose expansion for JSKN027 will be completed.

JSKN021

JSKN021 is a first-in-class dual payload ADC consisting of an EGFR/HER3 bispecific antibody conjugated with novel topoisomerase I inhibitor (T01) and Monomethyl auristatin E (MMAE). Engineered with finely tuned binding avidity in both arms to address tumor heterogeneity while minimizing on-target, off-tumor toxicity, JSKN021 was designed for enhanced stability and improved homogeneity. It combines T01 (DAR 4) and MMAE (DAR 2) payloads to overcome non-response and resistance observed with single-payload treatment strategies.

Events during the Reporting Period

  • In April 2025, preclinical data of JSKN021 were presented at the 2025 AACR Annual Meeting. The data demonstrated that JSKN021 inhibited the growth of cancer cells with either HER3 or EGFR or both expressions. Furthermore, JSKN021 showed stronger tumor inhibition efficacy than mono payload ADCs in multiple CDX models.

Events after the Reporting Period

  • In March 2026, the IND application for JSKN021 for the treatment of advanced malignant solid tumors was accepted by the CDE.

Expected Milestones in 2026 (from Q2 2026)

  • Dose escalation for JSKN021 will be completed.

KN046

KN046, a bispecific antibody (BsAb) immune checkpoint inhibitor, composed of a fusion of CTLA-4 and PD-L1 single domain antibody, engineered to target the tumor microenvironment with high PD-L1 expression. Multiple clinical trials of KN046 have been conducted in China, the United States and Australia.

Events during the Reporting Period

  • In February 2025, the results of phase II clinical study of KN046 in combination with lenvatinib for the treatment of advanced unresectable or metastatic hepatocellular carcinoma were published in Nature Communications.

Manufacturing Facilities

The Company’s manufacturing facility was constructed in compliance with GMP standards of the NMPA, the FDA, and the European Medicines Agency (EMA), with current capacity meeting the large-scale manufacturing needs for a variety of biologic both in the clinical and commercial stages. The new suite dedicated to ADC drugs has been already commenced operations, further strengthening the industrialization foundation of the ADC platform. In 2025, the Company successfully passed the GMP compliance inspection conducted by the Medicines Control Authority of Zimbabwe (MCAZ). In early 2026, it successively passed the cGMP inspection by the Saudi Food and Drug Authority (SFDA) and the GMP inspection by the Australian Therapeutic Goods Administration (TGA). The quality system continues to receive recognition from internationally authoritative regulatory agencies.

Other Highlights

  • In September 2025, at the 2025 China Healthcare Decision-makers Conference (2025 CHDC) and the China Innovative Drug Decade Achievement Tour organized by Pharmcube, the Company was listed on the “China Innovative Drug Decade Glory” honor roll and awarded the “Industry-leading Biotech Company”.
  • In November 2025, the Company was granted with “2025 Top 100 Chinese Pharmaceutical Innovative Enterprises” for the seventh time at the 17th China Healthcare Summit of Entrepreneurs, Scientists, and Investors (2025 CHSESI).
  • In December 2025, the Company was granted the “Annual Innovation Award” at the Annual Excellence Company Selection organized by Gelonghui.

For more information, please refer to the Company’s Annual Results Announcement for the Year Ended December 31, 2025 published on the Hong Kong Stock Exchange and the Company’s official website.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.

Huawei Cloud Supports Humanica’s Digital Transformation with Reliable and Scalable Cloud Infrastructure

BANGKOK, March 26, 2026 /PRNewswire/ — Huawei Cloud is supporting the digital transformation of Humanica, Thailand’s leading provider of world-class end-to-end HR and ERP solutions, by delivering reliable and scalable cloud infrastructure that enhances system performance, operational efficiency, and service reliability.

By migrating its HR and ERP systems to Huawei Cloud, Humanica has strengthened its digital foundation with a cloud-native architecture, enabling faster service deployment and more responsive support for the growing needs of enterprises across Southeast Asia.

Humanica combines its proprietary HR technology platform with professional payroll outsourcing services to help organizations streamline HR management and automate business processes. As demand for its services continues to grow, the company requires a more flexible and resilient cloud foundation to support expanding workloads and rapidly evolving market needs.

While Humanica’s initial success was built on a robust foundation of traditional colocation and monolithic architecture, the company’s rapid regional expansion has necessitated a shift toward a more elastic and automated digital infrastructure. To meet the growing demand for its services across Southeast Asia, Humanica has sought to move beyond the physical lead times and manual configuration cycles of legacy hardware models. This evolution is driven by a commitment to enhancing operational agility and ensuring that Humanica remains at the forefront of HR technology innovation.

Through its collaboration with Huawei Cloud, Humanica has successfully transitioned to a modern cloud environment designed for agility, reliability, and scalability. Huawei Cloud is the first cloud provider in Thailand to offer three Availability Zones (3AZ), providing advanced redundancy mechanisms that ensure high availability and uninterrupted service operations. Leveraging this infrastructure, Humanica has deployed its workloads across multiple zones for maximum resilience.

Building on this cloud foundation, Humanica’s engineering team has implemented a comprehensive cloud-native stack, including container orchestration, automated deployment pipelines, and an integrated monitoring and observability platform, significantly simplifying operations and accelerating delivery. With these capabilities, Humanica’s engineering teams can focus exclusively on pioneering next-generation HR features and accelerating strategic service expansion across the region.


“Huawei Cloud is committed to supporting enterprises in their digital transformation journeys with secure, reliable, and high-performance cloud technologies,” said Ms. Celine Cao, CEO of Huawei Cloud Thailand.

“Our collaboration with Humanica demonstrates how cloud innovation can help organizations modernize their infrastructure, improve operational efficiency, and accelerate business growth.”

Huawei Cloud provides a comprehensive portfolio of cloud solutions that support enterprise workloads, including cloud infrastructure, cloud-native development capabilities, hybrid cloud architecture, and advanced security services. Its unified architecture allows organizations to seamlessly integrate public and private cloud environments while maintaining local data management.

The platform also offers robust database services such as RDS for SQL Server, which provide intelligent management tools for backup, restoration, performance optimization, and resource monitoring. To ensure enterprise-grade protection, Huawei Cloud integrates comprehensive security services, including Identity and Access Management (IAM), Network Address Translation (NAT) Gateway, and Security Groups, while complying with more than 130 global security certifications.

Since adopting Huawei Cloud as its infrastructure foundation, Humanica has achieved significant operational improvements. The company can now scale its IT resources five times faster, reducing provisioning time from weeks to minutes through automated infrastructure orchestration. This agility has enabled Humanica to accelerate new feature releases and onboard enterprise customers more rapidly, strengthening its competitive position in the HR technology market.


“By leveraging Huawei Cloud’s cloud-native infrastructure and local support capabilities, we have strengthened the reliability, security, and scalability of our platform,” said Mr. Soontorn Dentham, CEO of Humanica. “This enables us to accelerate product innovation, deliver more stable services to our customers, and continue supporting organizations in their digital transformation journeys.”As enterprises increasingly embrace cloud technologies to drive innovation and efficiency, Huawei Cloud continues to provide secure, scalable, and intelligent solutions that empower businesses to unlock new opportunities in the digital era.

Video for reference: https://www.youtube.com/watch?v=l5JNjnzd7U8

About Huawei
Founded in 1987, Huawei is a leading global provider of information and communications technology (ICT) infrastructure and smart devices. The company has more than 207,000 employees and operates in more than 170 countries and regions, serving more than three billion people around the world.

Its mission is to bring digital technology to every person, home, and organization for a fully connected, intelligent world. To this end, Huawei drives ubiquitous connectivity and promotes equal access to networks; brings cloud and artificial intelligence to all corners of the world to provide superior computing power where and when it is needed; builds digital platforms to help industries and organizations become more agile, efficient, and dynamic; and redefines user experience with AI, making it more personalized in all aspects of life, whether at home, in the office, or on the go.

About Humanica
Humanica Public Company Limited is Thailand’s leading world-class HR technology provider, offering a comprehensive suite of Human Capital Management solutions and professional payroll outsourcing services. With over 22 years of experience serving enterprises across Southeast Asia; Humanica empowers organizations to streamline HR operations and drive digital transformation through its proprietary, cloud-native technology platform.

Laos-China Railway Surpasses 80 Million Tonnes of Cargo Since Late 2021

The China-Laos Railway has transported more than 80 million tonnes of cargo since it opened in December 2021, including 18 million tonnes of cross-border goods. (Photo credit: People's Daily)

The Laos-China Railway (LCR) has transported more than 80 million tonnes of cargo since its launch in December 2021, cementing its place as one of Southeast Asia’s most consequential trade corridors in just over four years of operation.

Of that total, more than 18 million tonnes crossed international borders across a network now serving 19 countries and regions, including Thailand, Vietnam, Malaysia, and Singapore, Chinese state media reported.

Daily cross-border services have risen from just two trains at launch to a peak of 23, while the variety of goods has expanded from roughly ten commodity types, primarily fertilizers and rubber, to more than 3,800, now spanning chemicals, textiles, electrical products, and minerals.

So far in 2026, 5.64 million tonnes have already been transported.

Millions of passengers, one day’s journey

As the LCR marked four years of operation on 3 December 2025, it had carried more than 62.5 million passenger trips, including nearly 640,000 cross-border journeys. The fastest end-to-end journey now takes just 9 hours and 36 minutes, shrinking what was once a multi-day overland trek into a single day’s travel.

For Laos, the 1,035-kilometer line running from Kunming in China’s Yunnan Province south to Vientiane, has opened the country to faster, more reliable regional connections, with Lao produce, minerals, agricultural products now reaching the markets at lower cost, and Vientiane as a growing distribution hub for the wider subregion.

The next link: a Mekong bridge and beyond

That role is set to expand. 

A planned Mekong railway bridge at Vientiane would connect the LCR to Thailand’s new high-speed rail project, extending the corridor further south through Thailand toward Malaysia and Singapore, completing a continuous rail link from Kunming to the tip of the Malay Peninsula. 

With Laos’ capital sitting at the pivotal junction, the LCR is fast becoming the central spine of China’s Belt and Road Initiative in mainland Southeast Asia.

The jump from ten goods categories to more than 3,800 in just four years signals a maturing, diversified trade route. 

If current momentum holds, cumulative cargo could reach 100 million tonnes before the end of 2026.

Boao: Where the World Meets | Qionghai: Where Free Trade Thrives

Global Health Tech Debuts as Qionghai Leads the Wellness Wave


QIONGHAI, CHINA – Media OutReach Newswire – 26 March 2026 – From March 24-27, the ” Boao: Where the World Meets, Qionghai: Where Free Trade Thrives” City Exhibition was held at Boao’s Dongyu Island Cultural Park. This marks the first major city showcase since the launch of Hainan Free Trade Port’s island-wide special customs operations—providing a panoramic window into Qionghai’s role as a core functional zone of the free trade port. Woven with the theme of global connection and open development, the exhibition turns policies and culture into immersive, sensory experiences through innovative technology and design.

Photo

The opening hall’s “Digital Twin Experience Pod” offers a glimpse into daily life in tomorrow’s Qionghai—all through the use of an identity card. The interactive “Cycle Through Qionghai” installation takes guests on a dynamic ride along the Wanquan River, through historic Nanyang hometowns—settlements built by overseas Chinese returning from Southeast Asia, and into Qionghai’s stunning coastal and mountain scenery.

A key highlight is the frontier technology from the Boao Lecheng International Medical Tourism Pilot Zone. Breakthrough innovations—including the world’s first automatic exophthalmometer, a non-invasive glucose monitor, a facial recognition system for genetic screening, and the Ruiwatch wearable—made their collective public debut, showcasing how “global medical innovations meet their first patients in China.”

As China’s only Medical Tourism Special Zone, Qionghai is not just a hub of medical “tech marvels”—it is a natural wellness destination. It brings together world-class medical devices, privileged treatment policies, and international health management systems, making “access to global cutting-edge healthcare” an everyday reality. From Lecheng’s precision medicine to seaside healing, from Traditional Chinese Medicine wellness to sports recovery, Qionghai is building an integrated ecosystem of medical care, wellness, tourism, and living.

With the Free Trade Port now in full operation, this coastal city invites health seekers worldwide to begin a journey of total renewal—where advanced medicine meets natural vitality, right here in Qionghai.
Hashtag: #CultureandTourismofGuizhouProvince #Qionghai

The issuer is solely responsible for the content of this announcement.